Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE V TORRES OLMEDA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1346473709
CMS profile
1255258
Location
COTO LAUREL, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,389.24

145 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,369.62 144
Education $19.62 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE V TORRES OLMEDA

NPI 1346473709 · CMS profile ID 1255258

Allopathic & Osteopathic Physicians / Internal Medicine

COTO LAUREL, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346473709?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE V TORRES OLMEDA, NPI 1346473709, CMS profile ID 1255258. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346473709?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JORGE V TORRES OLMEDA, NPI 1346473709, CMS profile ID 1255258. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346473709?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JORGE V TORRES OLMEDA, NPI 1346473709, CMS profile ID 1255258, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1346473709?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

145 matching records · $3,389.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 145 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–145 of 145.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $16.7604/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000279971 CMS
Dexcom, Inc. $100.7704/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054655163 CMS
Dexcom, Inc. $20.4304/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054655113 CMS
AbbVie Inc. $10.4004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999282953 CMS
Merck Sharp & Dohme LLC $19.0204/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048863495 CMS
PFIZER INC. $19.4004/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050370543 CMS
Boston Scientific Corporation $136.2904/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022072983 CMS
Novo Nordisk Inc $20.1004/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000272645 CMS
Merck Sharp & Dohme LLC $22.8603/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048746207 CMS
GlaxoSmithKline, LLC. $87.9403/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002021811 CMS
PFIZER INC. $19.2503/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050393675 CMS
Amgen Inc. $16.8003/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019975703 CMS
Mylan Specialty L.P. $28.8303/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039084689 CMS
AstraZeneca Pharmaceuticals LP $22.0003/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014375357 CMS
Novo Nordisk Inc $13.7003/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000272619 CMS
AstraZeneca Pharmaceuticals LP $18.4503/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011739813 CMS
Amgen Inc. $16.2803/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020607477 CMS
Regeneron Healthcare Solutions, Inc. $24.4403/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999497041 CMS
GlaxoSmithKline, LLC. $26.7503/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002023687 CMS
Genentech USA, Inc. $96.9203/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040411391 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $125.0003/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996950029 CMS
Abbott Laboratories $21.8703/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018439036 CMS
GlaxoSmithKline, LLC. $17.9503/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002021877 CMS
Merck Sharp & Dohme LLC $20.5402/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048350159 CMS
AbbVie Inc. $33.8302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999282949 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.6702/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000291707 CMS
AstraZeneca Pharmaceuticals LP $18.2702/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011254955 CMS
Amgen Inc. $15.2102/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019975701 CMS
PFIZER INC. $21.4102/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050530239 CMS
PFIZER INC. $19.2302/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049283671 CMS
Amgen Inc. $18.5302/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020607475 CMS
GlaxoSmithKline, LLC. $18.2102/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002025679 CMS
Novo Nordisk Inc $13.4502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000272613 CMS
PFIZER INC. $20.4701/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049105008 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2301/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996950025 CMS
Lilly USA, LLC $15.6201/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031639937 CMS
Abbott Laboratories $21.5001/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018439465 CMS
Merck Sharp & Dohme LLC $19.2601/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048350167 CMS
AstraZeneca Pharmaceuticals LP $22.6301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016179063 CMS
GlaxoSmithKline, LLC. $26.9001/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002027359 CMS
Dexcom, Inc. $22.2601/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054655093 CMS
PFIZER INC. $28.5801/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050545513 CMS
Amgen Inc. $13.6801/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020607473 CMS
AbbVie Inc. $14.9301/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999282945 CMS
Daiichi Sankyo Inc. $18.3001/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006370645 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,290.22 141
PY2020 $2,680.34 138
PY2021 $3,114.68 147
PY2022 $3,280.03 157
PY2023 $3,389.24 145
PY2024 $3,134.37 137
PY2025 $3,885.94 151

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $27,150.22 12
PY2019 Principal investigator $44,934.65 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $10.87 08/20/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742919927
Principal investigator 1 PFIZER INC. $206.57 06/18/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954551
Principal investigator 1 PFIZER INC. $4,920.35 05/21/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954609
Principal investigator 1 PFIZER INC. $791.00 05/14/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954249
Principal investigator 1 PFIZER INC. $678.00 05/14/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954283
Principal investigator 1 PFIZER INC. $678.00 05/14/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954611
Principal investigator 1 PFIZER INC. $1,000.00 05/11/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954253
Principal investigator 1 PFIZER INC. $1,000.00 05/11/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954549
Principal investigator 1 PFIZER INC. $3,748.50 05/11/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954553
Principal investigator 1 PFIZER INC. $1,750.00 05/11/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954605
Principal investigator 1 PFIZER INC. $1,000.00 05/11/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742954673
Principal investigator 1 PFIZER INC. $11,366.93 02/06/2020 Non-covered Recipient Entity
CLINICAL RESEARCH OF CENTRAL FLORIDA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 742968055